190 results on '"myelodysplastic syndrome"'
Search Results
2. Case report: VEXAS syndrome with excellent response to treatment with azacitidine
3. Beneficial effects of cellular immunotherapy in the prevention and treatment of posttransplant hematologic relapse of myelodysplastic neoplasms
4. Anti-synthetase and myelodysplastic syndromes with deep morphea: an example of shared immunopathogenesis? A case-based review
5. WT1 gene mutations impact post-transplant relapse in myelodysplastic syndrome with excess blasts 2 patients
6. Systemic inflammatory autoimmune disease before allogeneic hematopoietic stem cell transplantation is a risk factor for death in patients with myelodysplastic syndrome or chronic myelomonocytic leukemia
7. Decitabine-containing conditioning improved outcomes for children with higher-risk myelodysplastic syndrome undergoing allogeneic hematopoietic stem cell transplantation
8. TP53-mutated acute myeloid leukemia and myelodysplastic syndrome: biology, treatment challenges, and upcoming approaches
9. Atypical presentation of Pearson syndrome in an infant with suspected myelodysplastic syndrome
10. Hypomethylating agents (HMAs) show benefit in AML rather than in intermediate/high-risk MDS based on genetic mutations in epigenetic modification (EMMs): from a retrospective study
11. The graft-versus-leukemia effect of prophylactic donor lymphocyte infusions after allogeneic stem cell transplantation is equally effective in relapse prevention but safer compared to spontaneous graft-versus-host disease
12. Research use only and cell population data items obtained from the Beckman Coulter DxH800 automated hematology analyzer are useful in discriminating MDS patients from those with cytopenia without MDS
13. The new WHO and ICC classification systems for myelodysplastic syndromes and their impact on the clinical laboratory
14. Allogeneic transplantation of bone marrow versus peripheral blood stem cells from HLA-identical relatives in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukemia: a propensity score analysis of a nationwide database
15. ERCC6L2-related disease: a novel entity of bone marrow failure disorder with high risk of clonal evolution
16. Covid-19-induced cavernous sinus thrombosis in a myelodysplastic syndrome patient: case report
17. A phase 1 study of IDH305 in patients with IDH1R132-mutant acute myeloid leukemia or myelodysplastic syndrome
18. Phase 1 study of belinostat and adavosertib in patients with relapsed or refractory myeloid malignancies
19. TLS/FUS-ERG fusion gene in acute leukemia and myelodysplastic syndrome evolved to acute leukemia: report of six cases and a literature review
20. Dose-finding trial of azacitidine as post-transplant maintenance for high-risk MDS: a KSGCT prospective study
21. The prognostic value of the controlling nutritional status score in patients with myelodysplastic syndrome
22. EAHP 2020 workshop proceedings, pediatric myeloid neoplasms
23. Novel inhibitor of hematopoietic cell kinase as a potential therapeutic agent for acute myeloid leukemia
24. Acute graft-versus-host disease increase risk and accuracy in prediction model of transplantation-associated thrombotic microangiopathy in patients with myelodysplastic syndrome
25. Single-agent 5-azacytidine as post-transplant maintenance in high-risk myeloid malignancies undergoing allogeneic hematopoietic cell transplantation
26. The impact of oral hypoglycemics and statins on outcomes in myelodysplastic syndromes
27. Epigenetic therapy in combination with a multi-epitope cancer vaccine targeting shared tumor antigens for high-risk myelodysplastic syndrome - a phase I clinical trial
28. Long-term outcomes following the addition of granulocyte colony-stimulating factor-combined high-dose cytarabine to total body irradiation and cyclophosphamide conditioning in single-unit cord blood transplantation for myeloid malignancies
29. New heritable ATRX mutation identified by whole exome sequencing and review
30. Infectious Microecology of the Hematological System
31. Monitoring treatment with 5-Azacitidine by flow cytometry predicts duration of hematological response in patients with myelodysplastic syndrome
32. The prognostic value of the Fibrinogen-Albumin Ratio Index in patients with myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes treated with azacitidine
33. A Mathematical Model of Myelodysplastic Syndromes: The Effect of Stem Cell Niches
34. Analysis of the impact of adherence to guidelines and expert advice in patients with myelodysplastic syndromes
35. Characterization of myelodysplastic syndromes progressing to acute lymphoblastic leukemia
36. Cytogenetic Diagnosis of Myelodysplastic Syndromes
37. Myelodysplastic Syndrome in Children
38. Management of Patients with Myelodysplastic Syndromes: Introductory Concepts
39. Molecular Biology of Myelodysplasia
40. Etiology and Epidemiology of MDS
41. Hemopoietic Cell Transplantation
42. Myelodysplastic Syndrome
43. Myelodysplastic Syndromes
44. Very-low-dose decitabine treatment for patients with intermediate- or high-risk myelodysplastic syndrome: a retrospective analysis of thirteen cases
45. How to treat myelodysplastic syndrome with clinical features resembling Behçet syndrome: a case-based systematic review
46. Evolving therapies for lower-risk myelodysplastic syndromes
47. Impact of marrow blasts percentage on high-grade myelodysplastic syndrome assessed using revised international prognostic scoring system
48. t(11;16)(q23;p13)/KMT2A-CREBBP in hematologic malignancies: presumptive evidence of myelodysplasia or therapy-related neoplasm?
49. The New WHO Classification for Akute Myeloid Leukemias and Myelodysplastic Syndromes
50. Myelodysplastic Syndromes
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.